Detection of Lung Cancer Risks for Serum Metabolomics

血清代谢组学检测肺癌风险

• 批准号: 8010636
• 负责人: Leo L Cheng
• 金额: $ 18.42万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8010636
• 关键词: Adenocarcinoma; Biochemistry; Biological; Blood; Blood Tests; Blood specimen; Cancer Control; Cancer Detection; Cancer Intervention and Surveillance Modeling Network; Cancer Patient; Cancerous; Cardiac Output; Clinic; Clinical; Coupled; Data; Detection; Development; Diagnosis; Disease; Eligibility Determination; Future; General Population; Genomics; Goals; Histopathology; Knowledge; Lesion; Lung; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of lung; Measures; Metabolic; Methods; Modeling; Monitor; Non-Small-Cell Lung Carcinoma; Pathology; Patients; Positron-Emission Tomography; Reading; Reporting; Research; Resources; Risk; Sampling; Screening procedure; Sensitivity and Specificity; Serum; Specimen; Squamous cell carcinoma; Staging; Structure of parenchyma of lung; Survival Rate; Symptoms; Techniques; Testing; Time; Tissues; base; cancer proteomics; cancer risk; cancer type; clinical application; cost; design; disorder control; economic outcome; health economics; innovation; lung cancer screening; member; metabolomics; mortality; prevent; public health relevance; research study; success; tool

DESCRIPTION (provided by applicant): The alarmingly high lung cancer mortality rate is due mostly to the lack of effective screening protocols for the general public that can detect and diagnose the condition at early and asymptomatic stages. Current radiological examinations, including CT, MRI, and PET, can detect lesions in the lungs; however, their extremely high costs coupled with their unproven efficacies as screening tools have prevented their use in annual screening protocols for the general public. Analyses of blood samples may be a practical and acceptable resource for advancements in lung cancer screening that can advise patients with suspicious readings to seek immediate further radiological tests. In the era of genomics and proteomics, cancer metabolomics collectively evaluate the biological statuses of global metabolite alterations related to malignancy development and progression. Metabolomic profiles measured from cancerous tissues have shown better sensitivity in assessing patient clinical conditions than current histopathology. The aim of the proposed project is to establish lung cancer specific blood serum metabolomic profiles with enough sensitivity and specificity to indicate the necessity for further radiological tests. In this preliminary and exploratory study, we will analyze paired tissue and serum specimens from the same lung cancer patients by using a magnetic resonance spectroscopy method that we developed for intact specimen analyses, search and discover lung cancer tissue metabolomic profiles in connection with tissue pathologies, apply the parameters of these metabolomic profiles obtained from tissue to their corresponding serum spectroscopic data, and test these calculated serum profiles for their ability to identify and group cancer patients. The project is designed to test the hypothesis that serum metabolomic profiles calculated from tissue metabolomic profiles and corrected by quantitative tissue pathologies may have clinical applicability as an early lung cancer screening test for the general public prior to the development of disease symptoms. The specific aims of the project are: 1) To establish serum metabolomic profiles according to tissue metabolomic profiles measured from the same patients for SCC and adenocarcinoma; and 2) to evaluate the sensitivity and specificity of the established serum metabolite profiles for detection and categorization of lung cancers from these patients, and assess and evaluate the clinical utility of the researched lung cancer serum metabolomic marker for screening, using a model from the NCI's Cancer Intervention and Surveillance Modeling Network (CISNET). PUBLIC HEALTH RELEVANCE: This is an exploratory study of paired tissue and serum samples from various lung cancer patients. If successful, annual screening of serum metabolomic profiles established through the initiatives of this project will direct patients with suspicious serum profiles to advanced and expensive radiological tests to detect lung cancers at early and asymptomatic stages, and in turn increase overall patient survival rates and change the paradigm of current oncological clinics.

描述（由申请人提供）：令人震惊的高肺癌死亡率主要是由于缺乏为公众缺乏有效的筛查方案，该方案可以在早期和无症状阶段检测和诊断病情。当前的放射学检查，包括CT，MRI和PET，可以检测肺部的病变。但是，由于筛查工具，他们的成本极高，再加上未经证实的效力，阻止了它们在公众的年度筛查方案中使用。对血液样本进行分析可能是肺癌筛查中进步的实际资源，可以为可疑读数的患者提供直接进一步的放射学检查。在基因组学和蛋白质组学时代，癌症代谢组学共同评估了与恶性发展和进展有关的全球代谢物改变的生物学地位。与当前的组织病理学相比，从癌组织测得的代谢组学特征在评估患者临床状况方面的敏感性更好。拟议项目的目的是建立具有足够敏感性和特异性的肺癌特异性血清代谢组谱，以表明进行进一步放射学检测的必要性。在这项初步和探索性研究中，我们将通过使用磁共振光谱法分析来自同一肺癌患者的成对组织和血清标本，我们开发了我们为完整的标本分析而开发的，搜索和发现肺癌组织代谢型，并发现与组织的绩效相关的特性，以相关的验证，这些潮流效率与这些验证的特性相关的特性，这些指测性均可验证的这些验证物质的这些因素，并将其验证的验证性验证性的这些验证性的验证性数据及其验证性的这些验证物来验证，这些指定性的绩效效率可以与这些潮流相关。计算出的血清谱，以识别和分组癌症患者的能力。该项目旨在检验以下假设：从组织代谢组谱计算出的血清代谢组谱并通过定量组织病理学纠正可能具有临床适用性，作为在疾病症状发展之前对普通公众的早期肺癌筛查测试。该项目的具体目的是：1）根据从同一患者中测量的SCC和腺癌的组织代谢组学谱，建立血清代谢组学谱； 2）评估已建立的血清代谢物谱的敏感性和特异性，用于从这些患者中检测和分类肺癌，并使用NCI的癌症干预和跑步网络（CISNET）评估和评估研究的肺癌血清代谢标志物进行筛查的临床实用性（用于筛查）。 公共卫生相关性：这是对来自各种肺癌患者的配对组织和血清样品的探索性研究。如果成功，则通过该项目的计划建立的血清代谢组学特征的年度筛查将指导具有可疑血清谱的患者进行高级且昂贵的放射学测试，以在早期和无症状阶段检测肺癌，进而提高患者的整体存活率并改变当前肿瘤学诊所的范例。